| NICE Ref |
Title |
Date Issued by HSCB |
| TA234 |
Abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor |
05/01/2012 |
| TA233 |
Golimumab for the treatment of ankylosing spondylitis |
20/02/2012 |
| TA232 |
Retigabine for the adjunctive treatment of partial onset seizures in epilepsy |
05/01/2012 |
| TA230 |
Bivalirudin for the treatment of ST-segment-elevation myocardial infarction |
05/01/2012 |
| TA229 |
Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion |
05/01/2012 |
| TA228 |
Bortezomib and thalidomide for the firstline treatment of multiple myeloma |
05/01/2012 |
| TA227 |
Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer |
05/01/2012 |
| TA226 |
Rituximab for the first-line maintenance treatment of follicular non-Hodgkin’s lymphoma |
05/01/2012 |
| TA225 |
Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti- rheumatic drugs |
20/02/2012 |
| TA223 |
Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease |
05/01/2012 |
| TA222 |
Trabectedin for the treatment of relapsed ovarian cancer |
05/01/2012 |
| TA221 |
Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura |
05/01/2012 |
| TA220 |
Golimumab for the treatment of psoriatic arthritis |
20/02/2012 |
| TA216 |
Bendamustine for the first-line treatment of chronic lymphocytic leukaemia |
05/01/2012 |
| TA215 |
Pazopanib for the first-line treatment of advanced renal cell carcinoma |
05/01/2012 |
| TA208 |
Trastuzumab for the treatment of HER2-positive metastatic gastric cancer |
05/01/2012 |
| TA203 |
Liraglutide for the treatment of type 2 diabetes mellitus |
20/02/2012 |
| TA200 |
Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C |
05/01/2012 |
| TA199 |
Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis |
20/02/2012 |
| TA198 |
Tocilizumab for the treatment of rheumatoid arthritis |
05/01/2012 |
| TA197 |
Dronedarone for the treatment of non-permanent atrial fibrillation |
20/02/2012 |
| TA195 |
Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor |
05/01/2012 |
| TA193 |
Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia |
05/01/2012 |
| TA190 |
Pemetrexed for the maintenance treatment of non-small-cell lung cancer |
05/01/2012 |
| TA188 |
Human growth hormone (somatropin) for the treatment of growth failure in children |
05/01/2012 |
| TA187 |
Infliximab (review) and adalimumab for the treatment of Crohn’s disease |
05/01/2012 |
| TA186 |
Certolizumab pegol for the treatment of rheumatoid arthritis |
20/02/2012 |
| TA169 |
Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma |
05/01/2012 |
| TA166 |
Cochlear implants for children and adults with severe to profound deafness |
05/01/2012 |
| TA98 |
Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents |
14/09/2016 |
| TA75 |
Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C |
05/01/2012 |
| TA23 |
Temozolomide for the treatment of recurrent malignant gliomaC |
02/08/2016 |
| TA20 |
Riluzole for the treatment of Motor Neurone Disease |
01/08/2016 |
